Nanozyme in Alzheimer's Disease diagnostics and therapy

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative condition that has become an important public health problem of global concern, and its early diagnostic and etiological treatment of AD are critical areas of research. In the course of clinical treatment, approved clinical drugs mainly serve to slow down the disease process by relieving patients' clinical symptoms. However, these drugs do not target the cause of the disease, and the lack of specificity of these drugs has led to undesirable side effects in treatment. Meanwhile, AD is mainly diagnosed by clinical symptoms and imaging, which does not have the advantage of early diagnosis of the disease. Nanozymes have been extensively investigated for the diagnosis and treatment of AD with high stability and specificity. Therefore, this review summarizes the recent advances in various nanozymes for AD diagnosis and therapy, including with peroxidase-like activity gold nanozymes, iron nanozymes, with superoxide dismutase-like and catalase-like activity selenium dioxide nanozymes, platinum nanozymes, and peroxidase-like palladium nanozymes, among others. A comprehensive analysis of the therapeutic and diagnostic features of nanozymes for AD as well as the prospects and challenges of their clinical application is presented. Our goal is to advance this emerging topic by building on our own work and the new insights we have learned from others. This review will assist researchers to quickly understand relevant nanozymes therapeutic and diagnostic information and further advance the field of nanozymes in AD.